OncoMatch

OncoMatch/Clinical Trials/NCT04895709

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Is NCT04895709 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including BMS-986340 and BMS-936558-01 for cervical cancer.

Phase 1/2RecruitingBristol-Myers SquibbNCT04895709Data as of May 2026

Treatment: BMS-986340 · BMS-936558-01 · Docetaxel — The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Gastric Cancer

Esophageal Carcinoma

Colorectal Cancer

Non-Small Cell Lung Carcinoma

Head and Neck Squamous Cell Carcinoma

Renal Cell Carcinoma

Urothelial Carcinoma

Pancreatic Cancer

Melanoma

Ovarian Cancer

Triple-Negative Breast Cancer

Breast Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: standard-of-care therapies

Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.

Cannot have received: docetaxel (docetaxel)

Exception: Part 1C only

participants with prior docetaxel use for the advanced/metastatic setting will be excluded (Part 1C)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Community Cancer Institute · Clovis, California
  • USC/Norris Comprehensive Cancer Center · Los Angeles, California
  • Hoag Memorial Hospital Presbyterian · Newport Beach, California
  • Local Institution - 0062 · Iowa City, Iowa
  • John Theurer Cancer Center · Hackensack, New Jersey

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify